Gao Shen, Zhao Dong, Wang Miao, Zhao Fan, Han Xueyu, Qi Yue, Liu Jing
Department of Epidemiology, Beijing An Zhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.
Department of Epidemiology, Beijing An Zhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.
Can J Cardiol. 2017 Dec;33(12):1624-1632. doi: 10.1016/j.cjca.2017.07.015. Epub 2017 Jul 29.
Although basic research has suggested that oxidized low-density lipoprotein (ox-LDL) is involved in the pathogenesis of atherosclerosis, population observational studies have yielded conflicting results about the association between circulating ox-LDL and atherosclerotic cardiovascular disease (ASCVD). Therefore, we performed a systematic review and meta-analysis of currently available observational studies to verify the association between circulating ox-LDL and ASCVD.
We systematically searched PubMed and the Cochrane Library from their inception to March 27, 2017, for nested case-control studies, case-cohort studies, and prospective cohort studies on the relationship between ox-LDL and ASCVD. Studies that did not assess the hazard ratio, relative risk, or odds ratio of ox-LDL or did not adjust for other risk factors, or those without examination of ox-LDL before collection of ASCVD occurrences were excluded. The summarized effect size was combined using fixed effect models. Subgroup analyses were performed on the basis of study quality, study design, definition of ASCVD events, effect size types, types of ox-LDL assay, ox-LDL contrast level, and whether low-density lipoprotein cholesterol was adjusted in a multivariate model.
A total of 12 included studies consisted of 3 nested case-control studies, 1 case-cohort study, 5 hospital-based cohort studies, and 3 community-based cohort studies. The summary effect size of increased circulating ox-LDL was 1.79 (95% confidence interval, 1.56-2.05) for ASCVD. Similar associations were shown in all subgroups.
Our findings indicate that increased levels of circulating ox-LDL are associated with clinical ASCVD events. Further well designed community-based cohort studies or intervention studies are needed to confirm our findings.
尽管基础研究表明氧化型低密度脂蛋白(ox-LDL)参与动脉粥样硬化的发病机制,但关于循环ox-LDL与动脉粥样硬化性心血管疾病(ASCVD)之间的关联,人群观察性研究得出了相互矛盾的结果。因此,我们对现有观察性研究进行了系统评价和荟萃分析,以验证循环ox-LDL与ASCVD之间的关联。
我们系统检索了PubMed和Cochrane图书馆自建库至2017年3月27日期间关于ox-LDL与ASCVD关系的巢式病例对照研究、病例队列研究和前瞻性队列研究。未评估ox-LDL的风险比、相对风险或比值比,或未对其他风险因素进行调整的研究,或在收集ASCVD事件之前未检测ox-LDL的研究均被排除。汇总效应量采用固定效应模型合并。根据研究质量、研究设计、ASCVD事件的定义、效应量类型、ox-LDL检测方法类型、ox-LDL对照水平以及多变量模型中是否调整了低密度脂蛋白胆固醇进行亚组分析。
总共纳入12项研究,包括3项巢式病例对照研究、1项病例队列研究、5项基于医院的队列研究和3项基于社区的队列研究。ASCVD患者循环ox-LDL升高的汇总效应量为1.79(95%置信区间为1.56 - 2.05)。所有亚组均显示出类似的关联。
我们的研究结果表明,循环ox-LDL水平升高与临床ASCVD事件相关。需要进一步设计良好的基于社区的队列研究或干预研究来证实我们的发现。